

**Clene Nanomedicine Announces Preclinical Data Demonstrating a Novel Gold Nanocrystal as a Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual Meeting**

- Late breaking abstract presented in the 'Cutting Edge Developments in MS Research Session' at the third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held Feb 1-3, in San Diego, California
- Clene's Phase II VISIONARY-MS trial set to begin in the second half of 2018

SALT LAKE CITY, February 2, 2018 -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company developing a new therapeutic class of novel Clean Surface Nanotherapeutic (CSN™) drugs using an electro-crystal-chemistry drug development platform, announced today results from multiple preclinical studies demonstrating remyelination capabilities of CNM-Au8 as a potential treatment for multiple sclerosis and other demyelinating disorders. The data were presented as both a platform presentation and a poster presentation in the 'Cutting Edge Developments in MS Research' Session of the third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held Feb 1-3, in San Diego, California.

In data presented at ACTRIMS, CNM-Au8 demonstrated striking remyelination activity in two independent animal demyelination models of multiple sclerosis. One model used the ingested toxin cuprizone, and the other used injected lysolecithin to achieve demyelination of CNS neurons and spinal nerve axons, respectively. Statistically significant improvements in remyelination were demonstrated via quantitation of immunohistochemistry and transmission electron microscopy. Remyelination was observed in the lysolecithin model using Luxol fast blue staining and immunohistochemistry followed by quantitation of myelin markers, confirming CNM-Au8's robust remyelinating effects. Data demonstrating the catalytic enhancement of cellular bioenergetic processes as the mechanism of action of CNM-Au8 were also presented. Clene Nanomedicine collaborated with Prof. Stephen D. Miller of Northwestern University, and Prof. Robert Miller of George Washington University, and their respective labs on these studies.

"We are committed to developing this new therapeutic class of treatments that disrupts the old paradigms of drug discovery, and CNM-Au8, as our lead asset, is realizing this goal. The mechanism of action of this drug is unique and the therapeutic potential of CNM-Au8 for helping patients with demyelinating disorders is significant," said Rob Etherington, CEO of Clene Nanomedicine. "No other drugs approved for the treatment of MS have been shown

to remyelinate chronic MS-induced lesions. For this reason, we are looking forward to the launch of our VISIONARY-MS Phase 2 trial in the summer of 2018 with oral administration of CNM-Au8 in adults with Relapsing Remitting Multiple Sclerosis who suffer from chronic optic neuropathy.”

### **About Clene Nanomedicine**

Clene Nanomedicine, Inc., ([www.CleneNanomedicine.com](http://www.CleneNanomedicine.com)), is a privately held clinical-stage biopharmaceutical company, based in Salt Lake City, UT with technical R&D and manufacturing in Principio, MD. Clene was founded in December 2013.

Clene’s platform technology develops catalytically active metallic nanocrystals with oral availability. The nanocrystals are created by patent-protected technology that capitalizes on techniques from plasma physics, hydro electro-crystallization, and materials science. Clene’s first asset is CNM-Au8. Its second asset, CNM-G-AgZn17, is being readied to commence a Phase 1/2a anti-viral clinical study by 2019.

### **About CNM-Au8**

CNM-Au8 is being developed for remyelination of CNS disorders. CNM-Au8 is a novel oral gold nanocrystal suspension, which has demonstrated remyelination across multiple animal models of demyelination.

Clene will commence a Phase 2 Study to treat Chronic Visual Pathway Deficits (Optic Nerve or Optic Radiation Lesions) in patients with stable Relapsing-Remitting Multiple Sclerosis (RRMS) in 2018 to prove the remyelinating effects of CNM-Au8. RRMS is characterized as a demyelinating condition resulting in damage to the myelin sheath protective covering surrounding nerve fibers in the brain and spinal cord, with consequential loss of function. No therapy is currently approved in any global market for the remyelination of multiple sclerosis lesions.

### **Contact:**

**Clene Nanomedicine, Inc.**

**Rob Etherington, 650-676-9695; [Rob@Clene.com](mailto:Rob@Clene.com)**